Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091768 | 1.00 | MAOB (0.44) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL741084 | 0.89 | SLC6A2 (0.48) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL741083 | 0.89 | SLC6A2 (0.48) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL15304583 | 0.89 | SLC6A2 (0.48) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL1091288 | 0.89 | MAOB (0.44) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL3183936 | 0.89 | MAOB (0.44) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL3183943 | 0.89 | MAOB (0.44) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL220637 | 0.88 | MAOB (0.46) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL220638 | 0.88 | MAOB (0.46) | MAOBGPR119MAOACHRM2CHRM1 | |
| SCHEMBL14687597 | 0.88 | MAOB (0.43) | MAOBGPR119MAOACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989202-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2012-07-25 | — | — | EP | disclosed |
| US-8153797-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| EP-2311835-A1 | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch AS (DK) | 2011-04-20 | — | — | EP | disclosed |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | MAOB 6/4885GPR119 214/4885MAOA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.